Search filters
Filters
Clear All

Phase

  • 12
  • 39
  • 2
  • 26
  • 1
  • 16
  • 1
  • 251
  • 352
  • 262
  • 4
  • 25
  • 323

Found 352 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 19223 Open-Label Dose-Finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients with Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroeso

99 years or below
All genders
Please refer to Protocol Section 2.1.1 (Main objectives). Please refer to Protocol Section 2.1.2 (Primary endpoint(s). Please refer to Protocol Section 2.1.4 (Secondary endpoints).
Learn More

UPCC 30423: A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non- Hodgkin Lymphoma

99 years or below
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

S2114 A randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

99 years or below
All genders
To compare the progression-free survival in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (PR) on first imaging response by central review (day +30PET/CT scan) after commercial CD19 CAR T-cell therapy
Learn More

13523: Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma

99 years or below
All genders
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with metastatic leiomyosarcoma. Participants are being invited to participate in this research study because they have metastatic leiomyosarcoma.
Learn More

A051902: A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

99 years or below
All genders
This study evaluates the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs. Eligible participants will be those with stage I-IV CD30 negative peripheral T-cell lymphoma that has not been previously treated.
Learn More

UPCC 33423 A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (Lumin

99 years or below
All genders
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Learn More

EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

99 years or below
All genders
The primary objective of this study is to assess whether preoperative hemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of patients with high risk de-differentiated liposarcoma DDLPS) and leiomyosarcoma (LMS) as measured by disease-free survival.
Learn More

UPCC 32423 An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, A CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Direc

99 years or below
All genders
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy for the treatment of relapsed or refractory large B-cell lymphoma.
Learn More

UPCC 47423:A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

99 years or below
All genders
TrAVeRse is a multicenter, open-label, randomized, Phase II study of AVR in treatment naive MCL participants. The primary objective is to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at end of AVR induction will be randomized …
Learn More

UPCC 12023: Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation

99 years or below
All genders
Please refer to Protocol Section 2 (Study Hypothesis/Objectives). Please refer to Protocol Section 3.5 (Primary Endpoints). Please refer to Protocol Section 3.6 (Secondary Endpoints).
Learn More
291 - 300 of 352